Core Insights - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [2] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients with elevated LDL-C levels [2] - Esperion is advancing its next-generation program targeting ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design [2] Company Developments - Esperion will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 8:00 a.m. GMT [1] - The company continues to evolve through commercial execution, international partnerships, and advancements in its pre-clinical pipeline [3] Contact Information - Investor relations contact: Alina Venezia, email: investorrelations@esperion.com, phone: (734) 887-3903 [4] - Media contact: Tiffany Aldrich, email: corporateteam@esperion.com, phone: (616) 443-8438 [4]

Core Insights - Esperion is hosting a virtual key opinion leader (KOL) event to discuss the challenges of statin intolerance and its impact on patient outcomes, emphasizing the company's commitment to addressing this unmet need [1][2] Company Overview - Esperion Therapeutics is a commercial stage biopharmaceutical company focused on developing new medicines for patients at risk of cardiovascular disease, specifically targeting elevated low-density lipoprotein cholesterol (LDL-C) [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for this patient population, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [3] - Esperion is advancing its next-generation program focused on ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design [3] Industry Context - Cardiovascular disease is the leading cause of morbidity and mortality globally, with nearly 20% of patients discontinuing statin therapy within the first year, often without transitioning to alternative treatments [2] - The urgent need for innovative solutions in cardiovascular care is highlighted, as patients who discontinue statin therapy remain vulnerable to serious cardiovascular events [2]

Core Insights - Esperion announced acceptance of an oral and a poster presentation at the AHA Scientific Sessions 2025, highlighting ongoing research in cardiovascular health [1][2] Group 1: Presentations - The oral presentation will focus on bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events, based on a secondary analysis of the CLEAR Outcomes trial [2] - A poster presentation will discuss the effects of bempedoic acid on venous thromboembolism, derived from a post-hoc analysis of the CLEAR Outcomes trial [2] Group 2: Company Overview - Esperion Therapeutics is a commercial stage biopharmaceutical company dedicated to developing new medicines for patients with unmet needs, particularly those at risk for cardiovascular disease [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients struggling with elevated LDL cholesterol [3] - Esperion's CLEAR Cardiovascular Outcomes Trial involved nearly 14,000 patients, supporting the efficacy of its treatments [3] Group 3: Future Directions - Esperion is advancing its next-generation program focused on developing ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design [3][4] - The company aims to evolve into a leading global biopharmaceutical entity through commercial execution and international partnerships [4]

Core Insights - Esperion will report its third quarter 2025 financial results on November 6, 2025, before market opens, followed by a management webcast at 8:00 a.m. ET to discuss the results and provide business updates [1][2] Company Overview - Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing new medicines for unmet patient needs, particularly in cardiovascular disease [3] - The company has developed the only FDA-approved oral, once-daily, non-statin medications for patients at risk for cardiovascular disease with elevated LDL-C levels, supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients [3] - Esperion is advancing its next-generation program focused on ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design to create potent and specific inhibitors [3][4] Business Development - Esperion is evolving into a leading global biopharmaceutical company through effective commercial execution, international partnerships, collaborations, and the advancement of its pre-clinical pipeline [4]

Core Insights - Esperion Therapeutics (ESPR) has nominated ESP-2001, a specific allosteric ATP citrate lyase (ACLY) inhibitor, as a new preclinical development candidate for treating primary sclerosing cholangitis (PSC), a rare autoimmune liver disease with no approved treatments [1][7] - The company plans to initiate IND-enabling studies for ESP-2001 and submit an IND application to the FDA, aiming to start clinical studies in 2026 [2] - ESP-2001 has shown potential in reducing liver and bile duct injury, inflammation, and fibrosis in preclinical studies, indicating its ability to impact PSC progression [3] Company Developments - Esperion's stock rose by 5.2% following the announcement of ESP-2001 [2] - The collaboration with Evotec (EVO) was crucial in discovering ESP-2001, combining Esperion's expertise in ACLY therapy with Evotec's drug discovery platform [2][3] - The nomination of ESP-2001 triggered an undisclosed payment to Evotec [3] Financial Performance - Esperion's net product sales of Nexletol and Nexlizet in the U.S. grew by 42% in the first half of 2025, reaching $75.2 million, driven by increased prescription volumes [10] - Esperion aims to diversify its portfolio beyond cardiovascular diseases into the liver disorder market, targeting a potential market opportunity exceeding $1 billion annually with ESP-2001 [10] Market Position - Esperion currently holds a Zacks Rank of 3 (Hold) [11] - The company has two FDA-approved drugs, Nexletol and Nexlizet, which are marketed under different names in ex-U.S. markets [8][9]

Core Insights - Esperion has nominated ESP-2001, a highly-specific allosteric ATP citrate lyase (ACLY) inhibitor, for preclinical development targeting primary sclerosing cholangitis (PSC), a disease with no approved treatments [1][2] - The company aims to file an Investigational New Drug (IND) application with the FDA to initiate first-in-human clinical studies in 2026 [1][2] Company Developments - The nomination of ESP-2001 signifies a strategic expansion of Esperion's therapeutic focus beyond cardiovascular diseases [2] - Esperion continues its partnership with Evotec to utilize their INDiGO platform, which is designed to accelerate the development of small molecule drug candidates [3] Disease Overview - PSC is a rare autoimmune liver disease characterized by chronic inflammation and scarring of the bile ducts, leading to severe complications such as cirrhosis and liver failure [4][6] - There are approximately 76,000 diagnosed PSC patients in the U.S. and Europe, with no approved treatment options available [5] Market Opportunity - ESP-2001 represents a potential market opportunity exceeding $1 billion annually, given its exclusive global development and commercialization rights held by Esperion [5] - The drug may qualify for Orphan Drug and Fast Track designations from the FDA, as well as PRIME designation from the European Medicines Agency [5]

Core Insights - Esperion Therapeutics (ESPR) is conducting a secondary offering of 30 million shares at $2.50 per share, aiming to raise approximately $75 million in gross proceeds [1][7] - The stock price fell nearly 17% following the announcement due to the discounted pricing, which was 19% below the previous closing price of $3.09 [2][7] - The proceeds from the offering will be used to expand the commercial reach of marketed drugs Nexletol and Nexlizet, support clinical development, and for general corporate purposes [4][7] Financial Details - The secondary offering is expected to close today, with net proceeds estimated at $70.2 million after expenses [1] - The underwriters have an option to purchase an additional 4.5 million shares at the same price [1] Product Information - Nexletol and Nexlizet are marketed for treating elevated LDL-C and cardiovascular risk reduction, with Nexlizet being a combination of bempedoic acid and ezetimibe [5] - The company has settled patent litigation with Dr. Reddy's Laboratories, preventing the launch of generic versions of its drugs until April 19, 2040 [6] Legal Context - Esperion has signed similar agreements with other generic drugmakers, ensuring that they cannot market generics of Nexletol or Nexlizet until 2040 [8] - Ongoing patent litigation remains with other generic challengers, including Sandoz, Aurobindo Pharma, and MSN Pharmaceuticals [8] Market Performance - Year-to-date, ESPR's stock has gained 17%, outperforming the industry average growth of 10% [2]

Market Performance - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 100 points, closing at 46,751.12, a rise of 0.32% [1] - The NASDAQ rose by 0.88% to 22,989.73, and the S&P 500 gained 0.57% to 6,752.93 [1] - Information technology shares saw a notable increase of 1.1%, while consumer staples stocks fell by 0.4% [1] Commodities - Oil prices increased by 1.7%, reaching $62.78, while gold rose by 1.5% to $4,066.00 [5] - Silver prices surged by 2.7% to $48.780, whereas copper experienced a slight decline of 0.2% to $5.0860 [5] European Markets - European shares showed positive performance, with the eurozone's STOXX 600 rising by 0.86% [6] - Spain's IBEX 35 Index increased by 1.18%, London's FTSE 100 rose by 0.77%, Germany's DAX 40 gained 0.97%, and France's CAC 40 also rose by 1.18% [6] Asian Markets - Asian markets closed lower, with Japan's Nikkei 225 falling by 0.45%, Hong Kong's Hang Seng index down by 0.48%, and India's BSE Sensex declining by 0.19% [7] Company Updates - Dell Technologies Inc. saw its shares rise by 9% to $163.88, with Wells Fargo and Bernstein analysts raising their price targets to $180 [9] - Critical Metals Corp. shares surged by 15% to $11.50 after signing a 10-year offtake deal for 15% of rare earth output from the Tanbreez Project [9] - Select Medical Holdings Corporation shares increased by 13% to $14.71, with RBC Capital raising the price target from $16 to $20 [9] - Esperion Therapeutics, Inc. shares dropped by 19% to $2.4912 following a $75 million offering announcement [9] - Zeta Network Group shares fell by 47% to $1.81 after announcing a $15 million registered direct offering [9] - Envoy Medical, Inc. shares decreased by 38% to $0.9899 after announcing a $4 million registered direct offering [9]

Group 1: Penguin Solutions, Inc. - Penguin Solutions reported fourth-quarter earnings of 43 cents per share, exceeding the analyst consensus estimate of 38 cents per share [1] - The company reported quarterly sales of $337.922 million, which fell short of the analyst consensus estimate of $342.112 million [1] - For FY2026, Penguin Solutions projects adjusted earnings between $1.75 to $2.25 per share and sales ranging from $1.314 billion to $1.588 billion [2] - Following the earnings report, shares of Penguin Solutions dipped 17.6% to $22.24 in pre-market trading [2] Group 2: Other Companies - Esperion Therapeutics, Inc. saw a decline of 20.1% to $2.47 after announcing a public offering of common stock [4] - NOVONIX Limited experienced a drop of 12.7% to $1.79 after a previous increase of 14% [4] - NANO Nuclear Energy Inc. fell 9.1% to $51.50 following a $400 million oversubscribed private placement of common stock [4] - Joby Aviation, Inc. decreased by 8.5% to $17.30 after pricing a $513.9 million underwritten offering of common shares [4] - Archer Aviation Inc. declined 4.1% to $11.95 after a previous drop of more than 8% [4] - NextNRG Inc. fell 3.2% to $2.73 after a significant increase of 36% the previous day [4] - NuCana plc decreased by 3% to $6.81 in pre-market trading [4]

Group 1: Penguin Solutions, Inc. - Penguin Solutions reported fourth-quarter earnings of 43 cents per share, exceeding the analyst consensus estimate of 38 cents per share [1] - The company reported quarterly sales of $337.922 million, which fell short of the analyst consensus estimate of $342.112 million [1] - For FY2026, Penguin Solutions projects adjusted earnings between $1.75 to $2.25 per share and sales ranging from $1.314 billion to $1.588 billion [2] - Following the earnings report, shares of Penguin Solutions dipped 17.6% to $22.24 in pre-market trading [2] Group 2: Other Companies - Esperion Therapeutics, Inc. saw a decline of 20.1% to $2.47 in pre-market trading after announcing a public offering of common stock [4] - NOVONIX Limited experienced a drop of 12.7% to $1.79 in pre-market trading after a previous increase of 14% [4] - NANO Nuclear Energy Inc. fell 9.1% to $51.50 in pre-market trading due to a $400 million oversubscribed private placement of common stock [4] - Joby Aviation, Inc. decreased by 8.5% to $17.30 in pre-market trading after pricing a $513.9 million underwritten offering of common shares [4] - Archer Aviation Inc. declined 4.1% to $11.95 in pre-market trading after a previous drop of more than 8% [4] - NextNRG Inc. fell 3.2% to $2.73 in pre-market trading after a significant increase of 36% the previous day [4] - NuCana plc decreased by 3% to $6.81 in pre-market trading [4]